LONDON, UK, 20 May, 2008 - SkyePharma PLC (LSE: SKP) today announces
the presentation of its Phase III, long-term, open label safety study
evaluating FlutiformTM for the treatment of asthma in adolescent and
adult patients. The scientific poster will be shown today, during the
American Thoracic Society ("ATS") Meeting in Toronto, Canada.
